SLDB, US83422E2046

Solid Biosciences presents seven studies. Solid Biosciences stock is valued at USD 686.2 million

Published on 10/21/2026 at 00:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Seven studies are scheduled for ESGCT from October 27, 2026. Solid Biosciences stock was last at USD 6.40 on Nasdaq October 20, 2026.

Research calendar takes shape

Solid Biosciences announced seven accepted abstracts on October 20, 2026.
The ESGCT congress begins on October 27, 2026, with poster sessions following on October 28 and October 29, 2026.
Solid Biosciences stock was last at USD 6.40 at 4:00 p.m. ET on Nasdaq on October 20, 2026.

SLDB, US83422E2046, Illustration mit AI erstellt.

Solid Biosciences (ISIN US83422E2046) announced seven accepted abstracts for the European Society of Gene and Cell Therapy congress from October 27 to October 30, 2026. The release dated October 20, 2026, from GlobeNewswire said the presentations will cover SGT-003, the POLARIS-101 capsid platform and manufacturing research.

The research spans three fronts

The accepted work covers therapeutic design, next-generation delivery, capsid engineering and vector manufacturing. Solid said POLARIS-101 is being evaluated as the delivery capsid for SGT-003 in the Phase 1/2 INSPIRE DUCHENNE trial and the Phase 3 IMPACT DUCHENNE trial, according to GlobeNewswire. The company also said its manufacturing platform has optimized more than 200 operating parameters.

Three milestones mark the recent timeline

On October 1, 2026, Solid Biosciences announced inducement grants covering 8,150 restricted stock units, according to Solid Biosciences. On October 14, 2026, UBS initiated coverage with a Buy rating and a USD 20.00 price target, as Markets Insider reported. On October 20, 2026, the company announced the seven ESGCT abstracts.

What comes next for the program?

The ESGCT congress is scheduled to begin on October 27, 2026, in Hamburg, Germany. The first listed poster sessions are set for October 28, 2026, followed by additional presentations on October 29, 2026, according to GlobeNewswire. The schedule gives investors concrete dates for new technical detail on the lead program and the delivery platform.

Stock valuation stays clinical

Solid Biosciences stock was last at USD 6.40 at 4:00 p.m. ET on Nasdaq on October 20, 2026. The same quote showed a USD 686.2 million market capitalization, while the 52-week range was USD 3.79 to USD 11.45. The valuation therefore remains closely tied to clinical development and platform execution rather than commercial revenue.